Tag: ezutromid

June 27, 2018

Summit Therapeutics Announces PhaseOut DMD Did Not Meet Primary Endpoint

Summit Therapeutics (AIM:SUMM, NASDAQ:SMMT) announces PhaseOut DMD has not met its primary or secondary endpoints after 48 weeks of treatment...
April 19, 2018

Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial

Summit Therapeutics (NASDAQ:SMMT) announces the completion of ezutromid dosing in patients with Duchenne muscular dystrophy (‘DMD’) for the full 48-week...
April 11, 2018

Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018 and Operational Progress

Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM) reports its financial results for the fourth quarter and fiscal year ended 31 January 2018 and...
February 26, 2018

Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD

Summit Therapeutics (NASDAQ:SMMT) announces further positive findings from PhaseOut DMD, a Phase 2 open-label, multi-centre clinical trial of the utrophin...
January 25, 2018

Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial

Summit Therapeutics (NASDAQ:SMMT) the drug discovery and development company advancing therapies for rare diseases and infectious diseases, today announces positive...
November 16, 2016

Summit Enrolls US Patients into a Phase 2 Clinical Trial of Ezutromid

Summit Therapeutics, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, today announces...